Cerliponase alfa ▼ is not registered in all countries, and where it is registered the content of its indication along with other content may vary.
Please refer to your local prescribing information before prescribing cerliponase alfa.

▼ This medicinal product is subject to additional monitoring, special reporting is required in relation to adverse reactions. Email us at medinfo@bmrn.com for further details.

This website is sponsored and funded by BioMarin for healthcare professionals only.

Key Publications

A curated collection of scientific and clinical publications focussed on CLN2 and other forms of neuronal ceroid lipofuscinoses (NCLs). Reproduction of content owned by BioMarin on this page is authorised for non-commercial purposes. You may be required to clear additional rights if specific content depicts identifiable private individuals or includes third-party works. To use or reproduce content that is not owned by BioMarin (including but not limited to content compiled by BioMarin subject to a license from the original copyright holder), you may need to seek permission directly from the right-holders. Software or documents covered by industrial property rights, such as patents, trademarks, registered designs, logos, and names, are excluded from BioMarin’s reuse policy and are not licensed to you. 

Infographic

SUMMARY INFOGRAPHIC OF CLN2 GUIDELINES

Download a summary of the evidence and consensus-driven guidelines from an international panel of experts, that provides key insights and best practices in the management of CLN2 disease.

Read More